The University of Chicago Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Sean Pitroda and Ralph Weichselbaum.
Sean Pitroda
Connection Strength
17.432
Ralph Weichselbaum
  1. Reply to: Pre-clinical data interpretation requires clinical context. Nature. 2026 Aug; 656(8127):E5-E6.
    View in: PubMed
    Score: 0.988
  2. IFN signaling at the nexus of the radiotherapy response in malignant peripheral nerve sheath tumors. J Clin Invest. 2026 Mar 02; 136(5).
    View in: PubMed
    Score: 0.960
  3. Radiotherapy Duality in Metastatic Disease-Inhibiting Seeding, Unmasking Dormancy. JAMA Oncol. 2026 Jan 01; 12(1):24-25.
    View in: PubMed
    Score: 0.949
  4. Radiation-Induced Amphiregulin Drives Tumor Metastasis. Int J Radiat Oncol Biol Phys. 2026 Mar 15; 124(4):1065-1068.
    View in: PubMed
    Score: 0.936
  5. Immunoradiotherapy goes club(bing). Nat Cancer. 2021 09; 2(9):871-872.
    View in: PubMed
    Score: 0.703
  6. Integrated molecular and clinical staging defines the spectrum of metastatic cancer. Nat Rev Clin Oncol. 2019 09; 16(9):581-588.
    View in: PubMed
    Score: 0.612
  7. Integration of radiotherapy and immunotherapy for treatment of oligometastases. Lancet Oncol. 2019 08; 20(8):e434-e442.
    View in: PubMed
    Score: 0.608
  8. Author Correction: Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 11 13; 9(1):4827.
    View in: PubMed
    Score: 0.579
  9. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nat Commun. 2018 05 04; 9(1):1793.
    View in: PubMed
    Score: 0.558
  10. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104.
    View in: PubMed
    Score: 0.379
  11. MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment. Proc Natl Acad Sci U S A. 2009 Apr 07; 106(14):5837-41.
    View in: PubMed
    Score: 0.296
  12. Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis. Cancer Cell. 2026 Sep 17.
    View in: PubMed
    Score: 0.249
  13. Amphiregulin as a Mediator of Radiation-Induced Systemic Effects in Metastatic Cancer: Balancing Local Control with Distant Progression. Clin Cancer Res. 2025 Dec 01; 31(23):4899-4902.
    View in: PubMed
    Score: 0.236
  14. Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function. J Exp Med. 2026 01 05; 223(1).
    View in: PubMed
    Score: 0.235
  15. Publisher Correction: Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 Nov; 647(8091):E9.
    View in: PubMed
    Score: 0.234
  16. Correction: Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2025 Oct 06; 222(10).
    View in: PubMed
    Score: 0.233
  17. The dark side of radiotherapy. Cancer Cell. 2025 Aug 11; 43(8):1385-1389.
    View in: PubMed
    Score: 0.229
  18. Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease. Clin Cancer Res. 2025 Jul 01; 31(13):2556-2564.
    View in: PubMed
    Score: 0.229
  19. Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade. Nat Genet. 2025 Aug; 57(8):1802-1811.
    View in: PubMed
    Score: 0.229
  20. Radiation-induced amphiregulin drives tumour metastasis. Nature. 2025 07; 643(8072):810-819.
    View in: PubMed
    Score: 0.227
  21. No disease left behind. Oncotarget. 2025 Mar 13; 16:163-166.
    View in: PubMed
    Score: 0.224
  22. YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production. J Clin Invest. 2024 12 02; 134(23).
    View in: PubMed
    Score: 0.220
  23. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024 08; 25(8):e352-e362.
    View in: PubMed
    Score: 0.215
  24. Sharing the Burden: The Case for Definitive Local Therapy in Place of Immune Checkpoint Blockade for Patients With a Low-Volume Burden of Metastatic Disease. J Clin Oncol. 2024 10 10; 42(29):3387-3391.
    View in: PubMed
    Score: 0.215
  25. Radiotherapy and immunology. J Exp Med. 2024 07 01; 221(7).
    View in: PubMed
    Score: 0.212
  26. Epitranscriptional regulation of TGF-ß pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. J Clin Invest. 2023 12 15; 133(24).
    View in: PubMed
    Score: 0.206
  27. RNA m6A methylation and MDSCs: Roles and therapeutic implications for radiotherapy. Med. 2023 12 08; 4(12):863-874.
    View in: PubMed
    Score: 0.206
  28. YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer Cell. 2023 07 10; 41(7):1294-1308.e8.
    View in: PubMed
    Score: 0.198
  29. Author Correction: Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2023 Feb; 55(2):355.
    View in: PubMed
    Score: 0.194
  30. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Nat Cancer. 2022 12; 3(12):1498-1512.
    View in: PubMed
    Score: 0.191
  31. Tumor aneuploidy predicts survival following immunotherapy across multiple cancers. Nat Genet. 2022 12; 54(12):1782-1785.
    View in: PubMed
    Score: 0.191
  32. A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
    View in: PubMed
    Score: 0.190
  33. Beyond the Visible Spectrum: Considering the Oligometastatic Hypothesis in the Light of a New Era. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):581-586.
    View in: PubMed
    Score: 0.190
  34. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022 09; 19(9):585-599.
    View in: PubMed
    Score: 0.186
  35. Combined radio-immunotherapy: An opportunity to increase the therapeutic ratio of oligometastasis-directed radiotherapy. Neoplasia. 2022 05; 27:100782.
    View in: PubMed
    Score: 0.182
  36. Radiotherapy and immunotherapy: open questions and future strategies. Trends Cancer. 2022 01; 8(1):9-20.
    View in: PubMed
    Score: 0.178
  37. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
    View in: PubMed
    Score: 0.177
  38. Radiotherapy and Immunotherapy Combinations in the Treatment of Patients with Metastatic Disease: Current Status and Future Focus. Clin Cancer Res. 2021 10 01; 27(19):5188-5194.
    View in: PubMed
    Score: 0.177
  39. Treatment of Cancer with Radio-Immunotherapy: What We Currently Know and What the Future May Hold. Int J Mol Sci. 2021 Sep 03; 22(17).
    View in: PubMed
    Score: 0.176
  40. The Spectrum of Metastasis: An Opportunity for Cure? Semin Radiat Oncol. 2021 07; 31(3):174-179.
    View in: PubMed
    Score: 0.174
  41. Suppression of local type I interferon by gut microbiota-derived butyrate impairs antitumor effects of ionizing radiation. J Exp Med. 2021 03 01; 218(3).
    View in: PubMed
    Score: 0.170
  42. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med. 2021 02 24; 13(582).
    View in: PubMed
    Score: 0.169
  43. (Oligo)metastasis as a Spectrum of Disease. Cancer Res. 2021 05 15; 81(10):2577-2583.
    View in: PubMed
    Score: 0.168
  44. Oligometastasis: Past, Present, Future. Int J Radiat Oncol Biol Phys. 2020 11 01; 108(3):530-538.
    View in: PubMed
    Score: 0.166
  45. Cytoreduction and the Optimization Of Immune Checkpoint Inhibition with Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):17-26.
    View in: PubMed
    Score: 0.164
  46. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020 Mar/Apr; 26(2):96-99.
    View in: PubMed
    Score: 0.158
  47. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019 09 02; 10(1):3959.
    View in: PubMed
    Score: 0.153
  48. Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 09; 14(9):1510-1512.
    View in: PubMed
    Score: 0.151
  49. Staging the Metastatic Spectrum Through Integration of Clinical and Molecular Features. J Clin Oncol. 2019 05 20; 37(15):1270-1276.
    View in: PubMed
    Score: 0.149
  50. Oligometastatic prostate cancer: Reality or figment of imagination? Cancer. 2019 02 01; 125(3):340-352.
    View in: PubMed
    Score: 0.145
  51. JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers. Mol Cancer Ther. 2018 04; 17(4):732-739.
    View in: PubMed
    Score: 0.138
  52. Low Recombination Proficiency Score (RPS) Predicts Heightened Sensitivity to DNA-Damaging Chemotherapy in Breast Cancer. Clin Cancer Res. 2017 Aug 01; 23(15):4493-4500.
    View in: PubMed
    Score: 0.129
  53. Ad.Egr-TNF and Local Ionizing Radiation Suppress Metastases by Interferon-ß-Dependent Activation of Antigen-specific CD8+ T Cells. Mol Ther. 2010 May; 18(5):912-920.
    View in: PubMed
    Score: 0.126
  54. Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. Sci Rep. 2016 10 24; 6:35854.
    View in: PubMed
    Score: 0.125
  55. microRNAs and oligometastasis. Aging (Albany NY). 2015 Mar; 7(3):146-7.
    View in: PubMed
    Score: 0.112
  56. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget. 2015 Feb 28; 6(6):3540-52.
    View in: PubMed
    Score: 0.112
  57. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014 Mar 26; 6(229):229ra42.
    View in: PubMed
    Score: 0.105
  58. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics. 2010 May 06; 3:16.
    View in: PubMed
    Score: 0.080
  59. Ad.Egr-TNF and local ionizing radiation suppress metastases by interferon-beta-dependent activation of antigen-specific CD8+ T cells. Mol Ther. 2010 May; 18(5):912-20.
    View in: PubMed
    Score: 0.079
  60. STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect. BMC Med. 2009 Nov 05; 7:68.
    View in: PubMed
    Score: 0.077
  61. STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One. 2009 Jun 08; 4(6):e5821.
    View in: PubMed
    Score: 0.075
  62. MUC1-induced transcriptional programs associated with tumorigenesis predict outcome in breast and lung cancer. Cancer Res. 2009 Apr 01; 69(7):2833-7.
    View in: PubMed
    Score: 0.074
  63. Translational strategies exploiting TNF-alpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr; 16(4):373-81.
    View in: PubMed
    Score: 0.072
  64. m 6 A-dependent microRNA binding to chromatin-associated RNA for transcriptional activation. bioRxiv. 2026 Mar 11.
    View in: PubMed
    Score: 0.060
  65. Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. Lancet Oncol. 2025 Mar; 26(3):e152-e170.
    View in: PubMed
    Score: 0.056
  66. Radiotherapy Enhances Metastasis Through Immune Suppression by Inducing PD-L1 and MDSC in Distal Sites. Clin Cancer Res. 2024 May 01; 30(9):1945-1958.
    View in: PubMed
    Score: 0.053
  67. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial. JAMA Oncol. 2023 09 01; 9(9):1245-1254.
    View in: PubMed
    Score: 0.050
  68. Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition. Clin Cancer Res. 2023 08 01; 29(15):2761-2766.
    View in: PubMed
    Score: 0.050
  69. Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference. Oncoimmunology. 2023; 12(1):2222560.
    View in: PubMed
    Score: 0.050
  70. ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.
    View in: PubMed
    Score: 0.048
  71. Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.
    View in: PubMed
    Score: 0.046
  72. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.
    View in: PubMed
    Score: 0.045
  73. Evaluation of Initial Metastatic Tumor Location and Radiation Response to Determine Outcomes in Patients Who Received Combination Stereotactic Body Radiotherapy and Immunotherapy for NSCLC. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e449.
    View in: PubMed
    Score: 0.044
  74. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. J Thorac Oncol. 2022 01; 17(1):130-140.
    View in: PubMed
    Score: 0.044
  75. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.
    View in: PubMed
    Score: 0.043
  76. Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial. Clin Cancer Res. 2020 12 15; 26(24):6437-6444.
    View in: PubMed
    Score: 0.041
  77. DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs. Cancer Res. 2019 02 01; 79(3):650-662.
    View in: PubMed
    Score: 0.036
  78. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618.
    View in: PubMed
    Score: 0.034
  79. Advanced Animal Model of Colorectal Metastasis in Liver: Imaging Techniques and Properties of Metastatic Clones. J Vis Exp. 2016 11 30; (117).
    View in: PubMed
    Score: 0.032
  80. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer. 2016 07 15; 122(14):2242-50.
    View in: PubMed
    Score: 0.030
  81. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs. Oncotarget. 2016 May 03; 7(18):26496-515.
    View in: PubMed
    Score: 0.030
  82. Imaging of tumor clones with differential liver colonization. Sci Rep. 2015 Jun 22; 5:10946.
    View in: PubMed
    Score: 0.029
  83. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer. 2015 Jul 14; 113(2):327-35.
    View in: PubMed
    Score: 0.028
  84. MUC1-C activates the TAK1 inflammatory pathway in colon cancer. Oncogene. 2015 Oct 01; 34(40):5187-97.
    View in: PubMed
    Score: 0.028
  85. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91.
    View in: PubMed
    Score: 0.026
  86. Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells. PLoS One. 2012; 7(7):e39432.
    View in: PubMed
    Score: 0.023
  87. Cooperativity of the MUC1 oncoprotein and STAT1 pathway in poor prognosis human breast cancer. Oncogene. 2010 Feb 11; 29(6):920-9.
    View in: PubMed
    Score: 0.019
  88. Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol. 2009 May; 85(5):421-31.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.